Vasamed EBIT per Employee
The EBIT per Employee of Vasamed (VSMD) as of Aug 16, 2026 is -88,225.81 USD.
Get this data via API
Financial Data API
EBIT per Employee
-88,225.81USD
Last updated:
EBIT per Employee of Vasamed is 2026 -88,225.81 USD. EBIT per Employee of Vasamed was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Vasamed Stock analysis
What does Vasamed do? Vasamed Inc is an American company specializing in medical devices and diagnostics. It was founded in 1987 and is headquartered in St. Paul, Minnesota. Vasamed has become a leading manufacturer of devices for non-invasive vascular diagnostics and therapy, as well as for the assessment of vascular function and circulation.
Vasamed's business model is based on selling and marketing medical devices and accessories to doctors, hospitals, and medical facilities worldwide. The company aims to provide its customers with innovative, high-quality medical devices and services that help improve patient diagnosis and treatment outcomes.
In recent years, Vasamed has continuously expanded its product range. The company operates in various sectors, including the growing treatment options for circulatory and cardiovascular diseases. At the same time, the company also offers products and services to support science and research.
In the field of "vascular diagnostics," Vasamed offers devices for determining circulatory disorders, such as laser taxis, ankle-brachial index systems, and laser doppler blood flow measurement devices. These devices are excellent for detecting diseases such as peripheral arterial occlusive disease (PAOD) or diabetes, which are known risk factors for the development of circulatory disorders.
In the field of "endothelial function," Vasamed offers devices for measuring vascular health, such as the Endo-PAT system. This system is a non-invasive procedure for measuring the endothelial function of blood vessels, which is important for the prevention of cardiovascular diseases.
In the "research and development projects" sector, the company collaborates with academic partners and industry researchers to develop new technologies and diagnostic and therapeutic procedures. Vasamed also participates in clinical trials and scientific conferences to present its research findings and products worldwide.
Vasamed has a long history in medical diagnostics and therapy. The company has become one of the leading manufacturers of devices for non-invasive vascular diagnostics and therapy, as well as for the assessment of vascular function and circulation. Taking into account the experience and science that Vasamed has developed, the company aims to support medical professionals in the diagnosis and treatment of patients. Vasamed is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Vasamed stock
EBIT per Employee of Vasamed is -88,225.81 USD in 2026.
On Eulerpool you can find the complete historical development of EBIT per Employee Vasamed since 2006 – with annual values, charts, and detailed analysis.
EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.
EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Vasamed historically and in real time.
Access this data via the Eulerpool API
Workforce — Vasamed
All Key Metrics — Vasamed
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth